secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042630
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic reports Q4 2024 net loss $12.4M; positive TX45 Phase 1b interim results
--------------------------------------------------------------------------------

- TX45 Phase 1b Part A reduced PCWP by 17.9% in PH-HFpEF and PVR >30% in CpcPH subgroup.
- Completed ~$185.0M private placement in Feb 2025; cash runway into Q4'28.
- Cash and equivalents $141.2M at Dec 31, 2024; Q4 net loss $12.4M vs $7.9M year ago.
- APEX Phase 2 trial topline results expected in 2026; Phase 1b Part B results expected 2H'25.
- TX2100 Phase 1 initiation expected Q4'25 or Q1'26 for hereditary hemorrhagic telangiectasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000095017025042630/0000950170-25-042630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000095017025042630/tecx-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer